Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011860 (
type 2 diabetes
)
57,723
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Phosphoserine aminotransferase 1
(
PSAT1
) is an enzyme participating in serine synthesis. A role of
PSAT1
in the regulation of insulin sensitivity, however, is unknown. In this study, we showed that hepatic
PSAT1
expression and liver serine levels are reduced in genetically engineered leptin receptor-deficient (db/db) mice and high-fat diet (HFD)-induced diabetic mice. Additionally, overexpression of
PSAT1
by adenovirus expressing
PSAT1
improved insulin signaling and insulin sensitivity in vitro and in vivo under normal conditions. Opposite effects were observed when
PSAT1
was knocked down by adenovirus expressing small hairpin RNA specific for
PSAT1
(Ad-shPSAT1). Importantly, overexpression of
PSAT1
also significantly ameliorated insulin resistance in diabetic mice. In addition,
PSAT1
inhibited the expression of hepatic tribbles homolog 3 (TRB3) in vitro and in vivo, and adenoviruses expressing small hairpin RNA against TRB3-mediated inhibition of TRB3 reversed the attenuated insulin sensitivity in Ad-shPSAT1 mice. Interestingly, we found that serine mediates
PSAT1
regulation of TRB3 expression and insulin signaling in vitro. These results identify a novel function for hepatic
PSAT1
in regulating insulin sensitivity and provide important insights in targeting
PSAT1
for treating insulin resistance and
type 2 diabetes
. Our results also suggest that nonessential amino acid serine may play an important role in regulating insulin sensitivity.
...
PMID:Hepatic Phosphoserine Aminotransferase 1 Regulates Insulin Sensitivity in Mice via Tribbles Homolog 3. 2550 42